Imaging for staging bladder cancer: A clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595

BJU International

Volumn 87, Issue 1, 2001, Pages 39-46

  Hughes, O D M ^a   Perkins, A C ^b   Frier, M ^b   Wastie, M L ^b   Denton, G ^b   Price, M R ^b   Denley, H ^a   Bishop, M C ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bladder cancer; Monoclonal antibody; MUC1 mucin; Radio immunoscintigraphy; Staging

Indexed keywords

INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MUCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MALE; METASTASIS; PRIORITY JOURNAL;

EID: 0035155743     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.00985.x     Document Type: Article

References (30)

1. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: Comparison with final pathological stage in invasive bladder cancer
2. Diagnostic procedures
3. Staging of advanced bladder cancer: Current concepts and pitfalls
4. Magnetic resonance imaging of urinary bladder cancer
5. Computerised tomography: An unreliable method for accurate staging of bladder tumours in patients who are candidates for radical cystectomy
6. Diagnostic imaging of urothelial cancer
7. Gadolinium enhanced magnetic resonance imaging in the staging of urinary bladder neoplasms
8. Pelvic adenopathy from prostate and bladder carcinoma: Detection with T-weighted three-dimensional magnetisation prepared rapid gradient echo
9. Lymph node staging for bladder cancer by positron emission tomography
10. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium labelled monoclonal antibody CYT-356
11. 99mtechnetium-labelled monoclonal antibody CYT-351
12. Factors influencing pharmacokinetics, dosimetry and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumours
13. Tumour imaging of bladder carcinomas and their metastases with 111-indium labelled monoclonal anti-CEA antibody BW 431/26
14. Mucin expression by transitional cell carcinomas of the bladder
15. C595 - A monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas
16. Targeting of bladder cancer with monoclonal antibody NCRC48 - A possible approach for intravesical therapy
17. Bladder cancer targeting with 67Cu-labelled anti-MUC1 mucin antibody NCRC48 - A novel approach for intravesical therapy
18. Targeting superficial bladder cancer by the intravesical administration of copper-67 labelled anti-MUC1 mucin monoclonal antibody C595
19. The preparation and characterisation of 111ln labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy
20. Determination of the immunoreactive fraction of radiolabelled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
21. Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (In-111-NCRC48) defining polymorphic epithelial mucin
22. Polymorphic epithelial mucins (PEM): Molecular characteristics and association with breast cancer
23. Inhibition of the hepatocyte uptake of monoclonal antibodies by cheating agents
24. Comparative in vitro and in vivo studies of the stability of 111ln labelled and biotinylated CDTA or DTPA monoclonal antibody conjugates
25. Biodistribution of 111ln labelled engineered human antibody CTMO1 in ovarian cancer patients: Influence of protein dose
26. Production and characterisation of a recombinant anti-MUC1 scFv reactive with human carcinomas
27. Production and characterisation of an anti-(MUC1 mucin) recombinant diabody
28. Vehicles, chelators and radionuclides: Choosing the building blocks of an effective therapeutic radioimmunoconjugate